QurAlis gears up for clinical development of therapeutic candidate, QRL-101

(BUSINESS WIRE)–QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reports.